ANN ARBOR, Mich., – August 19, 2024 –Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company” or “Kraig Labs”), announces today that it has completed the third commercial spider silk production cycle. This cycle primarily focused on producing the Company’s BAM-1 recombinant spider silk hybrids, which marks the second successful commercial production cycle of the Company’s most advanced spider silk hybrids.

This production occurred during the region’s rainy season, a time of high humidity and heavy rains, which prevents most silk producers from operating. Kraig Labs actively chose to continue production during the rainy season to further challenge test the robustness and resilience of its BAM-1 hybrids. 

Operating during the rainy season helped to further optimize Kraig Labs’ silkworm colony and identify the best performers and future colony expansion. Renowned sericulture expert Dr. Nirmal Kumar is with the production team to analyzing all of the data collected during this rearing cycle and guiding the team to optimize the BAM-1 parental lines for continued success and growth of spider silk production.  

Over the next two weeks, the Company will harvest the hybrid spider silk cocoons from this production cycle and send them to local reeling facilities. This batch of cocoons will be used to further refine reeling operations, improve efficiency, and produce additional finished spider silk for use and sale in end markets.

“There is no stiffer challenge for the robustness than operating during the rainy season. Our BAM-1 hybrids demonstrated that they are ready for the worst mother nature can throw at them,” said Company COO, Jon Rice. “Our team continues to hit new production and processing milestones with the BAM-1 hybrids as the catalyst for rapid and continuous growth in our scalable and commercially sustainable spider silk production.”

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

ANN ARBOR, Mich., – August 13, 2024 –Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company” or “Kraig Labs”), announces today that it has confirmed that the material performance of its commercially produced recombinant spider silk matches the exceptional strength and toughness of the Company’s previous small batch performance testing. The results of this testing open the doors for Kraig Labs to aggressively move forward with commercial production of its proprietary recombinant spider silk.

Testing was completed last week at the Company’s R&D headquarters, pitting samples of the Company’s commercially produced spider silk against samples of mundane silk in a head-to-head test. Using a high-precision tensile testing machine, multiple samples of each silk type were tested using high-frequency data sampling, monitoring force, and displacement. Yield strength, ultimate tensile strength, and elongation data were collected and analyzed, confirming the mechanical superiority of the Company’s spider silk.

This testing confirmed that there has been no loss in strength or toughness associated with this significant growth in production scale. While these results were expected, by Kraig Labs and its key production advisor, verifying that what works in the lab also works in the field under commercial production conditions was an important milestone.

“The results of this testing confirm the performance of our production spider silk, unlocking a scalable system for commercial sustainable spider silk production,” said Company COO, Jon Rice. “Having worked with these materials for some time, we are not at all surprised by these results. We are happy to have our expectations confirmed and the added confidence to continue to aggressively move forward with our spider silk production scale-up.”

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

Renowned Sericulture Expert, Dr. Nirmal Kumar, Rejoins Team to Oversee Operations

ANN ARBOR, Mich., – August 5, 2024 –Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company” or “Kraig Labs”), announces today that renowned sericulture expert, Dr. Nirmal Kumar, will rejoin the Company’s team in Asia to oversee completion of the second production cycle of BAM-1 spider silk hybrids.

Dr. Nirmal Kumar rejoins the team this week, as Kraig Labs prepares to cocoon and reel the second BAM-1 hybrid spider silk production batch. This production cycle will build on the success of the first production cycle completed in July. The recombinant spider silk generated from this production batch will be available for sale and use in end-market product development.

This production cycle is the second of many scheduled for this year as Kraig Labs continues the expansion of its BAM-1 production hybrids.

The production team leaders and Dr. Nirmal Kumar have remained in close daily communications over the last month, laying the groundwork and preparing the facilities for the BAM-1 hybrids, now in production. While in-person with the team, Dr. Nirmal Kumar will supervise the cocoon production and monitor cocoon quality and reeling characteristics. Dr. Nirmal Kumar will also lead and train the team in large-scale selective matings in preparation for a 10X increase in capacity as the rainy season concludes.

During this trip, Dr. Nirmal Kumar will also review the teams’ progress in building the facilities, staffing, and equipment necessary to sustain the Company’s growing operations and meet its metric-ton level spider silk production target.

“The BAM-1 hybrids, in production now, continue to show the same robustness and performance demonstrated in the spring production trials. Dr. Nirmal Kumar and our team have laid a strong foundation for the massive scale-up in spider silk production, which is now underway. I am very happy to have Dr. Nirmal Kumar rejoin our production team in person as we enter this exciting phase of the rearing cycle. 2024 has been, and will continue to be a breakout year for Kraig Labs,” said Company Founder and CEO, Kim Thompson. “The completion of this second production cycle for BAM-1 hybrids will solidify our production model and reaffirm our industry-leading position in cost-effective and eco-responsible spider silk production.”

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

ANN ARBOR, Mich., – July 29, 2024– Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company” or “Kraig Labs“), announces that it has entered the rapid growth rearing phase for its third spider silk production cycle of the season. During this phase, the silkworms grow exponentially in preparation for spinning the Company’s proprietary recombinant spider silk cocoons.

Over the last week, the Company has taken steps to add additional production space to accommodate the rapidly growing silkworms during this phase. The Company continues to closely monitor the health and performance of the entire silkworm colony during this period of significant growth. Reports from the Company’s rearing team continue to show that the BAM-1 Hybrids are the most robust production strain that the Company has ever fielded.

As previously reported, the Company has adopted a batch-rearing process to minimize overcrowding and level loading the need for fresh, dry mulberry during the traditional rainy season. This approach is designed to further support silkworm colony health and ensure optimal rearing and cocooning conditions.

“Kraig Labs has delivered a quantum leap in spider silk production capacity. This advancement was powered by our strategic investments in facilities, equipment, silkworm genetics, and building out a team with the knowledge and expertise to utilize those resources,” said Company COO, Jon Rice. “We are seeing significant breakthroughs in our business plan nearly every week as we methodically and systematically advance our production capacities for the world’s first cost-effective, commercially scalable spider silk.”

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

ANN ARBOR, Mich., – July 22, 2024– Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company” or “Kraig Labs“), announces the launch of its third and largest production cycle of the 2024 spider silk production season.

This cycle is being released in a set of scheduled batches, the first of which is already in production. This batch process is designed to address the upcoming peak of the rainy season while driving Kraig Labs toward its 2024 production volume goals.

This expanded production cycle was empowered by an additional production facility recently brought online. The Company is utilizing this newly constructed facility to support the continued expansion of silkworm rearing and silk production, avoiding the typical slowdowns due to rain.

Kraig Labs expects to bring additional facilities online over the next two months to increase its production footprint in support of its goal of delivering the first metric ton of spider silk to the global markets.

With each successive production cycle, the Company further validates its spider silk production model and that its specialized silkworms are ready for mass production. This now-fielded technology has broken through technical barriers, allowing for the large-scale commercial production of engineered spider silk using the cost-effective, time-tested, and established infrastructure for traditional silk.

“Our rearing operations continue to set new commercial spider silk production records. The first half of 2024 was a game-changer for the commercialization of spider silk, and we are expecting even greater things for the second half of the year,” said Company Founder and CEO, Kim Thompson. “This year has been an inflection point for Kraig Labs and for the limitless possibilities of spider silk commercialization.”

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

ANN ARBOR, Mich., – July 15, 2024– Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company” or “Kraig Labs”), announces today the completion of phase one construction for its production facility expansion. This project was completed on budget and on schedule. This facility is now ready to support the Company’s third production wave, which will begin this month. 

This additional production space will allow Kraig Labs to continue its production expansion during the rainy season when silk production is traditionally reduced. This new space provides the facilities for the Company to process, dry, and store fresh mulberry needed during the rainy season. With this new space, the Company can continue expanding its spider silk production.

Kraig Labs is also investing in a second, significantly larger project, constructing a new dedicated silkworm egg hatchery. This larger facility is expected to address the Company’s production needs for the next 12-18 months. Construction on this project is also underway. It is expected to be online before the end of the rainy season.

“These investments in production capacity expansion are a part of our systematic growth plan for commercial scale production of spider silk,” said the Company’s Founder and CEO, Kim Thompson. “These additional facilities will allow us to keep our foot on the accelerator, bringing cost-effective and eco-responsible spider silk to the global markets.”

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

ANN ARBOR, Mich., – July 8, 2024 –Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company” or “Kraig Labs”), announces today that it has signed a production agreement for the manufacturing of its recombinant spider silk technology. This production agreement builds upon the Company’s success with the rollout of its new spider silk production hybrids earlier this year.

Under the terms of this agreement, Kraig Labs will work with silk manufacturers to adapt their existing production facilities and networks to produce Kraig Labs proprietary spider silk.

The recently announced buildout of additional production facilities is a component of this agreement and the Company’s efforts to expand spider silk production.

“We are making big moves to bring commercial-scale spider silk manufacturing online. This agreement will allow us to expand our production foot print and capacity,” said Company Founder and CEO, Kim Thompson. “We will continue to take bold actions, take smart risks, and invest in endless possibilities that commercial scale spider silk has to offer.”

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

ANN ARBOR, Mich., – July 1, 2024 –Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company” or “Kraig Labs”), announces today that it has achieved full capacity at its current production location. Hitting this milestone was part of Kraig Labs’ expansion plans for the first half of 2024. The Company now reports that it is moving forward with its planned investment into additional production facilities.

Kraig Labs began planning for this factory expansion during the spring trials after witnessing the strong growth and robustness of its new spider silk hybrids.

This expansion is scheduled to take place in two waves. The first will address the near-term need for capacity during the upcoming rainy seasons, this will provide the needed secure space for production over the next several months. The second, larger project will address Kraig Labs’ longer-term need for hatchery space, which is expected to address production needs for the next 12-18 months.

Permitting for both of these projects has been approved and the Company is now moving forward with investment into both of these expansion projects. Construction for both investments has begun, with the first project expected to be completed within just a few weeks and the larger effort is scheduled to be completed by early fall.

“We have set ambitious goals for spider silk production in 2024, and we are committed to achieving and exceeding those targets,” said Company Found and CEO, Kim Thompson. “These investments into production capacity bring us one step closer to realizing our vision for cost-effective commercial scale production of spider silk.”

The Company expects to begin the third wave of recombinant spider silk production this month, focusing on scaling up the output of the parental lines for its production hybrids.

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

ANN ARBOR, Mich., – June 25, 2024 –Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company” or “Kraig Labs”), announces today that it has expanded its production of spider silk with the creation of the next generation of BAM-1 hybrid. 

Kraig Labs recently announced the successful production of the first BAM-1 hybrid cocoons early this month. That production cycle ended with the significantly scaled-up output of hybrid eggs. These eggs were produced through careful selective breeding of the BAM-1 parental strains raised during this rearing cycle.

Based on the strong results of the last production batch, Kraig Labs elected to increase egg production this cycle. This represents the largest egg production in the Company’s history. These eggs are slated for rearing within the next 30 days.

The Company’s team is coordinating its rearing efforts and operational plans, for the next 60 days, to optimize its spider silk output, while factoring in the August weather cycle, which typically sees a reduction in traditional silk production due to heavy rains and suboptimal rearing conditions.

“The first half of 2024 has been, objectively, the most productive time in the Company’s history,” said Founder and CEO Kim Thompson. “We set some very aggressive goals for the BAM-1 hybrids and the expansion of spider silk production. We are hitting our marks with the business model and production schedule as the BAM-1 hybrids continue to demonstrate the robustness and performance.”

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

ANN ARBOR, Mich., – June 17, 2024 –Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company” or “Kraig Labs”), announces today that it has successfully completed cocoon production for the first commercial production run of its BAM-1 hybrids. The Company launched the BAM-1 hybrids 30 days ahead of schedule based on the overwhelming success of its spring production trials.

During the spring trials, Kraig labs raised the two separate BAM-1 parental lines with overwhelming success. At the end of those trials, the BAM-1 parent lines were cross-mated to create this first batch of commercial production BAM-1 hybrids.

This rearing of the BAM-1 hybrids represents a 10X increase in production volume when compared to the spring trials. This cycle has generated more than 325 pounds of recombinant spider silk cocoons that will be processed into finished recombinant spider silk. This is the largest batch of recombinant spider silk cocoons ever produced.

The BAM-1 hybrids are the latest development in the Company’s commercialization of recombinant spider silk. They were specifically designed to address the identified need for improved robustness to meet large-scale spider silk manufacturing needs.

Having proven its production efficiency, the Company is now preparing for further commercial expansion of the BAM-1 parental lines and significant scale-up in BAM-1 hybrids. Based on the results of production operations, the Company remains confident that it will achieve its metric-ton-level spider silk production goal.

“This first commercial production rearing of BAM-1 hybrids was a great success, representing the largest single batch we have ever produced to date. This production batch is just the beginning of what we believe will be a very exciting and rapid scale-up of spider silk production in 2024,” said Company Founder and CEO, Kim Thompson. “We will continue to move forward, taking smart risks, as we lead the commercialization of cost-effective and eco-responsible spider silk.”

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com